Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 7.0%

Shares of NASDAQ LPCN opened at $3.99 on Friday. The stock has a fifty day moving average price of $3.24 and a 200 day moving average price of $4.05. The company has a market cap of $21.35 million, a P/E ratio of -5.25 and a beta of 1.52. Lipocine has a 12-month low of $2.68 and a 12-month high of $11.79.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35). The company had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.35 million.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC boosted its position in Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 at the end of the most recent quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.